Omeros

Glowing puzzle piece fitting into puzzle
Biotech

Novo Nordisk pens $2.1B deal for Omeros’ stalled PNH drug

After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo spied an opportunity to scoop up the rare disease drug.
James Waldron Oct 15, 2025 9:02am
plan B fail reroute road path trail miss

FDA delays Omeros' 2nd attempt at transplant drug’s approval

Aug 15, 2025 5:55am
Stock exchange concept

Omeros stock up after data analysis spurs BLA resubmission plan

Dec 19, 2024 10:54am
failure crash no fail rocket cancelled end

Omeros stops kidney disease phase 3 after interim review fail

Oct 16, 2023 8:45am
reins rider cowboy horse steady hands saddle

Omeros saddles up for 2nd charge at transplant drug approval

Mar 14, 2023 9:30am
clock calendar time late delayed alarm

Omeros' Hail Mary throw for blood clot med delayed at FDA

Aug 17, 2022 11:21am